You have 9 free searches left this month | for more free features.

Condition

Carcinoma, Non-Small-Cell Lung (2)

Advanced Cancer (1)

Lymphoma (1)

Solid Tumors (1)

Overall Status

Completed (2)

Active, not recruiting (1)

Sign in for free

Phase

phase 1 (2)

phase 2 (1)

Sponsor

Eli Lilly and Company (3)

Collaborator

Intervention

ly2875358 (3)

erlotinib (2)

gefitinib (1)

ly2875358 + erlotinib (1)

ly2875358 at part a highest dose (1)

ly2875358 at part a highest dose + trametinib (1)

Study Documents

Intervention Type

drug (3)

biological (2)

Funder Type

Industry (3)

Study Type

Interventional (3)

ly2875358

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

NSCLC Trial in Worldwide (LY2875358, Erlotinib)

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

LY2875358
Erlotinib

Herlev, Denmark
+41 more

Sep 2, 2021

Advanced Cancer Trial in United States (LY2875358, LY2875358 + erlotinib, LY2875358 at Part A highest dose)

Completed

Advanced Cancer

LY2875358
+3 more

La Jolla, California
+9 more

Feb 14, 2017

Solid Tumors, Lymphoma, NSCLC Trial in Chiba (LY2875358, Erlotinib, Gefitinib)

Completed

Solid Tumors
+2 more

LY2875358
+2 more

Chiba, Japan

For additional information regarding investigative sites for thi

Jun 4, 2015